Epirus Biopharmaceuticals, Inc. and mAbxience, a biopharmaceutical company specializing in research, development and manufacturing of biosimilars, have entered into a development and future distribution deal for Epirus’ lead program, BOW015 (infliximab, reference biologic Remicade), for Latin American markets, including Argentina, Chile, Ecuador, Paraguay, Uruguay, and Venezuela.

mAbxience is a wholly owned subsidiary of Chemo Group, a Spanish-based global healthcare corporation with annual revenues of approximately $1 billion. mAbxience will be responsible for regulatory submissions, using BOW015’s existing data package, and eventual commercialization in these select Latin American markets. mAbxience is a biopharmaceutical company specialized in research, development, and manufacturing of biosimilars for the treatment and/or prevention of several diseases in diverse therapeutic areas.

Epirus Biopharmaceuticals is a global biosimilar company with several biosimilar product candidates includes BOW015 (infliximab), BOW050 (adalimumab) and BOW070 (tocilizumab), which respectively have as reference products, Remicade, Humira and Actemra.

Source: Epirus Biopharmaceuticals